≥99% HPLCPre-filled pen

AOD9604

Name: AOD9604
Brand: Dripfy
Availability: InStock

What it is?

AOD9604 is a modified fragment of human growth hormone (HGH) studied specifically for fat metabolism signalling, positioned to capture lipolytic pathway effects without emphasising classic GH-driven growth outcomes. It is commonly discussed in protocols targeting stubborn fat depots and metabolic efficiency endpoints.

Dripfy Advantage

Selective fat-metabolism signalling: Designed to mimic HGH-associated fat-metabolism effects while reducing emphasis on growth-related signalling.
Lipolysis activation: Positioned to support fat breakdown pathways and utilisation of stored adipose as an energy substrate.
Lipogenesis inhibition: Associated with reduced signalling linked to new fat storage and adipose accumulation dynamics.
Metabolic neutrality focus: Frequently positioned with a goal of minimising disruption to glucose-related endpoints relative to broader endocrine approaches (context-dependent).
Targeted composition utility: Often selected where the protocol goal is localised or resistant fat reduction while tracking lean-mass maintenance endpoints.

Clinical Applications & Therapeutic Potential

Stubborn fat depot endpoints: Potential support for reductions in resistant adipose-depot markers, particularly when lifestyle variables are controlled.
Fat-metabolism optimisation: Potential improvements in lipolysis-related markers and overall fat-oxidation dynamics.
Lean-mass preservation framing: Often positioned for protocols seeking fat reduction without prioritising growth-hormone-driven hypertrophy signalling.
Diet/exercise-resistant areas: Commonly referenced for areas less responsive to conventional approaches, as part of structured recomposition strategies.

Composition & Formulation

Concept/Class: HGH-derived lipolytic fragment peptide (C-terminal fragment concept)
Format: Ready-to-use pre-filled pen

€413

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

AOD9604

Modified human growth hormone (hGH) fragment (investigational) · Pre-filled pen

C· Emerging evidence

AOD9604 is a modified fragment of human growth hormone (hGH) studied for effects on fat metabolism. It is positioned to stimulate lipolysis and to reduce lipogenesis signalling while minimising the classic growth-promoting actions of full-length growth hormone. Human evidence for meaningful weight or fat reduction remains limited and inconsistent.

Studied use areas

Fat-metabolism and lipolysis research
Body-composition and stubborn-fat endpoints
Metabolic-efficiency signalling studies

Safety & status

Investigational compound; it is not an approved weight-loss medicine and lacks robust human efficacy data
Should only be considered under physician-supervised, appropriately governed conditions
Quality and long-term safety of research-grade material are not guaranteed
No dosing is provided; any use would be individualised and determined by the treating physician

⚕ Clinical note: This is educational information, not medical advice. AOD9604 is investigational with limited and mixed human evidence; it is not a proven treatment, and any use requires qualified physician supervision.

Evidence: Grade C — investigational, with limited and inconsistent human data · References: Peer-reviewed growth-hormone-fragment and lipolysis research; Early-phase human metabolic-trial literature; Academic reviews of investigational weight-management peptides